Does treating with anti–PD-1 to improve glomerular health come without a cost?

Does treating with anti–PD-1 to improve glomerular health come without a cost? Reply.

“…As representatives for our entire team, we thank Jhaveri et al ( 1 ) for their insightful comments on our recent study investigating the increased expression of programmed cell death protein 1 (PD-1) in kidneys during aging and focal segmental glomerulosclerosis (FSGS) ( 2 ). In our manuscript, we showed that PD-1 was predominantly increased in podocytes and kidney tubular epithelial cells in both mice and humans.…”

“…In their response, Jhaveri and colleagues, experts in onco-nephrology, eloquently discuss the clinical kidney-specific adverse events (AEs) when using immune checkpoint inhibitors (ICI) in cancer patients ( 1 ). They provide important clinical insights and an up-to-date summary of the incidence and types of glomerular lesions, acute kidney injury, and acute interstitial nephritis observed in patients receiving ICI for cancer treatment ( 3 , 4 ).…”